Literature DB >> 23389325

[Hyperthyroidism].

M Schott1.   

Abstract

Thyrotoxicosis is mainly caused by autonomous adenomas of the thyroid gland and by Graves' disease. A less frequent cause for thyrotoxicosis is Hashimoto's thyroiditis. Thyrotoxicosis in autonomous adenomas and Graves' disease is caused by an increased thyroid hormone production whereas hyperthyroidism in Hashimoto's thyroiditis results from destruction of the thyroid gland. Drug therapy depends on the cause of the disease. Autonomous adenomas and Graves' disease are treated with methimazole and potentially with β-blockers. Regarding thyroid ablative therapy, radioiodine is mostly preferred compared to thyroidectomy. Drug therapy of Hashimoto's thyroiditis is purely symptomatic using β-blockers and rarely corticosteroids. Hyperthyroidism in pregnancy is a major issue and pregnant women in the first trimester are treated with propylthiouracil (PTU) whereas women in the second and third trimesters are treated with methimazole. The aim is to maintain the serum fT4 levels within the upper normal range.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389325     DOI: 10.1007/s00108-012-3196-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

1.  Evidence of fetal microchimerism in Hashimoto's thyroiditis.

Authors:  M Klintschar; P Schwaiger; S Mannweiler; S Regauer; M Kleiber
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

Review 2.  Clinical review about TRAb assay's history.

Authors:  Klaus Zöphel; Dirk Roggenbuck; Matthias Schott
Journal:  Autoimmun Rev       Date:  2010-06-04       Impact factor: 9.754

3.  A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.

Authors:  Susanne Neumann; Wenwei Huang; Elena Eliseeva; Steve Titus; Craig J Thomas; Marvin C Gershengorn
Journal:  Endocrinology       Date:  2010-04-28       Impact factor: 4.736

4.  Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children.

Authors:  Scott A Rivkees; Ana Szarfman
Journal:  J Clin Endocrinol Metab       Date:  2010-04-28       Impact factor: 5.958

5.  Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial.

Authors:  Silvia A Eskes; Erik Endert; Eric Fliers; Ronald B Geskus; Robin P F Dullaart; Thera P Links; Wilmar M Wiersinga
Journal:  J Clin Endocrinol Metab       Date:  2011-11-30       Impact factor: 5.958

6.  A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.

Authors:  S D Lytton; K A Ponto; M Kanitz; N Matheis; L D Kohn; G J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2010-03-17       Impact factor: 5.958

7.  Management of Grave's disease is improved by total thyroidectomy.

Authors:  Maria Annerbo; Peter Stålberg; Per Hellman
Journal:  World J Surg       Date:  2012-08       Impact factor: 3.352

8.  Use of anti-thyroid drugs in euthyroid pregnant women with previous Graves' disease.

Authors:  Tammy McNab; Jody Ginsberg
Journal:  Clin Invest Med       Date:  2005-06       Impact factor: 0.825

9.  Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).

Authors:  Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

10.  TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.

Authors:  Peter Laurberg; Göran Wallin; Leif Tallstedt; Mirna Abraham-Nordling; Göran Lundell; Ove Tørring
Journal:  Eur J Endocrinol       Date:  2008-01       Impact factor: 6.664

View more
  1 in total

Review 1.  [Autoimmune diseases of the thyroid gland].

Authors:  S Allelein; J Feldkamp; M Schott
Journal:  Internist (Berl)       Date:  2017-01       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.